CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-12 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −36,372 | $22.25 | $809K | 22,958 |
| 2025-03-12 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −36,372 | 28,288 | ||
| 2025-03-10 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +7,000 | $3.80 | $27K | 88,975 |
| 2025-03-10 | Tessari Eben CHIEF OPERATING OFFICER | Sale 10b5-1 | −12,409 | $21.06 | $261K | 76,566 |
| 2025-03-10 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −7,000 | 14,049 | ||
| 2025-02-10 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +7,000 | $3.80 | $27K | 95,975 |
| 2025-02-10 | Tessari Eben CHIEF OPERATING OFFICER | Sale 10b5-1 | −14,000 | $19.57 | $274K | 81,975 |
| 2025-02-10 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −7,000 | 21,049 | ||
| 2025-01-15 | Moat Ross CHIEF COMMERCIAL OFFICER | Grant or award | +1,118 | $16.00 | $18K | 22,854 |
| 2025-01-15 | Megna Michael R CHIEF ACCOUNTING OFFICER | Grant or award | +469 | $16.00 | $8K | 26,997 |
| 2025-01-13 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +7,000 | $3.80 | $27K | 102,975 |
| 2025-01-13 | Tessari Eben CHIEF OPERATING OFFICER | Sale 10b5-1 | −12,323 | $18.13 | $223K | 90,652 |
| 2025-01-13 | Tessari Eben CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,677 | $19.08 | $32K | 88,975 |
| 2025-01-13 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −7,000 | 28,049 | ||
| 2024-12-16 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +16,017 | $1.59 | $25K | 118,992 |
| 2024-12-16 | Tessari Eben CHIEF OPERATING OFFICER | Sale 10b5-1 | −23,017 | $20.44 | $470K | 95,975 |
| 2024-12-16 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −16,017 | 0 | ||
| 2024-12-09 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +18,860 | $11.10 | $209K | 41,818 |
| 2024-12-09 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −18,860 | $21.38 | $403K | 22,958 |
| 2024-12-09 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −18,860 | 21,552 |
Page 43 of 74 · 1,467 trades